Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
29 participants
OBSERVATIONAL
2020-12-31
2022-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
IL35 Level in Vitiligo
NCT05980390
Tissue-resident Memory T Cells Expression Among the Repigmentation Patterns Induced by NB-UVB Phototherapy in Vitiligo
NCT05506995
Thymic Stromal Lymphopoietin (TSLP) in Vitiligo
NCT03367273
Translational Assessment of Vitiligo According to Body Locations
NCT06068218
Histochemical Study of Vitiligo in Sohag University Hospital Patients
NCT05869942
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Detailed history taking including onset, course, duration of the disease, aggravating factors and received medications
* VASI score assessed in every patient.
* Patients photographed, divided into two groups early \& late cases and 3 mm punch biopsies will be taken from perilesional and non lesional skin.
* Biopsies processed and stained for CD8 \& CD69 in cases of early group, \& late group and controls by immunofluorescence.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Both genders.
* Early group: onset less than or equal 6 months.
* Late group: onset more than 6 months
Exclusion Criteria
* Age \< 14 years.
* Pregnant females
* Patient who received treatment of any type within the last 3 months for the late group.
* Patients with other skin diseases or immunosuppression
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kasr El Aini Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rana F Hilal, MD
Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hilal
Role: PRINCIPAL_INVESTIGATOR
Kasr El Ainy University Hospital, Faculty of medicine, Cairo University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kasr El Ainy University hospital
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TRMvit
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.